Breaking News

Security Company Awards Employees with Equivalent of 18-Salary Grant Canada comes from behind to defeat USA in thrilling gold medal match at U18 world hockey championship What makes inflatable tires a popular choice? Residents of the county can access free mental health programs Poll Shows More Americans Trust Trump on Economy and Inflation than Biden

Dr. Ira Zackon, a hematologist/oncologist with New York Oncology Hematology and a senior medical director with Ontada, discusses a new study that aimed to uncover racial and socioeconomic disparities in patients with chronic lymphocytic leukemia (CLL). The research analyzed data from over 12,000 patients with CLL from 2015 to 2023, during which time new and effective CLL therapies such as Bruton tyrosine kinase (BTK) inhibitors, BCL2 inhibitors, and antibodies were introduced. These advancements have significantly improved the lives of patients with CLL. However, the study also sought to explore how social determinants of health beyond medical treatments can impact patient outcomes.

The study utilized the iKnowMed electronic health record system part of the US Oncology Network, which is the largest group of community oncologists in the country. By examining data from a large and geographically diverse database over an 8-year period, researchers were able to identify trends in CLL treatment and outcomes for both Black and White patient populations. This analysis provided valuable insights into how race and socioeconomic factors may impact treatment and outcomes for patients with CLL in real-world community oncology settings.

The results of this study show that there are significant disparities in outcomes between Black and White patients with CLL. Black patients had higher rates of disease progression, relapse, and death compared to their White counterparts. Additionally, they were more likely to be treated with less effective regimens or receive delayed initiation of therapy. These disparities were found to be associated with lower socioeconomic status (SES), including lower education levels, income levels, and access to healthcare resources.

The study highlights the importance of addressing social determinants of health in order to improve outcomes for patients with CLL. As Dr. Zackon notes “This research underscores the need for us as physicians and healthcare providers to address the root causes of health disparities by addressing social determinants such as poverty, education level

Leave a Reply